Bipolar Disorder News and Research

Latest Bipolar Disorder News and Research

AstraZeneca launches new campaign on depression through Facebook and Twitter

AstraZeneca is launching a new campaign called "Take on Depression" through a "Take on Depression" Facebook page and a @FaceDepression Twitter feed to support, educate, and inspire those affected by bipolar depression and major depressive disorder (MDD), also known as depression.

15 Oct 2010

Researchers use brain imaging to differentiate pediatric bipolar disorder, ADHD

Researchers at the University of Illinois at Chicago are the first to use brain imaging to examine the effects of emotion on working memory function in children with pediatric bipolar disorder or attention deficit hyperactivity disorder.

13 Oct 2010

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

H. Lundbeck A/S (Lundbeck) and Merck, known outside the United States and Canada as MSD, today announced a commercialization agreement for SYCREST (asenapine) sublingual tablets (5 mg, 10 mg). Under the terms of the agreement, Lundbeck will pay an undisclosed fee as well as product supply payments in exchange for exclusive commercial rights to SYCREST in all markets outside the United States, China and Japan. Lundbeck expects to launch SYCREST in the European Union (EU), where it is already approved, at the beginning of 2011.

12 Oct 2010

NCQA recertifies Lilly's online Health Education Answers program

Lilly's Health Education Answers program, an interactive online health and wellness tool, has received Health Information Product Recertification from the National Committee for Quality Assurance (NCQA).

11 Oct 2010

Valeant announces Alexza's receipt of FDA CRL for AZ-004 NDA

Valeant Pharmaceuticals International, Inc. announced today that Alexza Pharmaceuticals, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Alexza's New Drug Application (NDA) for AZ-004 (Staccato® loxapine) submitted as Adusuve™ Staccato® (loxapine) inhalation aerosol, 5 mg and 10 mg.

11 Oct 2010

FDA issues CRL for AZ-004 NDA application

Alexza Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for AZ-004 (Staccato loxapine), submitted as Adusuve Staccato (loxapine) inhalation aerosol, 5 mg and 10 mg.

11 Oct 2010

NBF's Brilliance in Bipolar Initiative receives Congressman Kennedy's endorsement

Congressman Patrick Kennedy, a long-time advocate for people living with mental illness, and Marc Kullman, co-founder of the National Bipolar Foundation, joined efforts to help reduce the stigma associated with bipolar disorder. The Brilliance in Bipolar Initiative is a national and collaborative effort to draw attention to and develop a better understanding of bipolar disorder.

6 Oct 2010

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.

6 Oct 2010

Repligen Corporation completes patient enrollment in RG2417 Phase 2b clinical trial

Repligen Corporation reported today that it has completed enrollment of patients in its Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.

30 Sep 2010

Teens who experience manic phase of bipolar disorder more likely to engage in high risk sexual behaviors

Although research has shown that teens with mental health disorders are more likely to engage in high risk sexual behaviors, like unprotected sex, a new study from the Bradley Hasbro Children's Research Center suggests there is an additional risk associated with certain psychiatric diagnoses.

29 Sep 2010

USC, Las Encinas Hospital to study on schizophrenia, bipolar disorder in younger, older adults

Schizophrenia and bipolar disorder affect 3% to 4% of the world's population, or about 222 million adults worldwide. In the United States, bipolar disorder affects about 5.7 million adult Americans 18 and older. Bipolar disorder, or manic depression, is a serious brain disorder that causes extreme shifts in mood, energy and functioning. People with the disorder experience episodes of mania and depression that can last from days to months. These symptoms usually begin in late adolescence, but can begin in early childhood or as late as a person's 40s or 50s. There is a strong genetic component related to bipolar disorder.

28 Sep 2010

Depression and anxiety disorders common in loved ones of breast cancer patients: Study

Earlier studies have shown that women living with breast cancer are at a risk of depression but new studies have shown that their partners are at a similar risk. The study looked at more than a million men enrolled in a nationwide Danish health registry followed for 13 years.

28 Sep 2010

Antipsychotics slightly raise risk for blood clots

Antipsychotics or medications that are used to treat psychiatric illnesses such as schizophrenia and bipolar disorder are reported to raise the risk of dangerous blood clots.

23 Sep 2010

Haven Behavioral Hospital offers treatment programs for adults with psychiatric illnesses

Haven Behavioral Hospital of Eastern Pennsylvania announced today it is offering acute intensive, inpatient and partial day treatment programs for adults with major psychiatric illnesses. The hospital will operate within the downtown campus of St. Joseph Medical Center and will offer services for adults suffering from schizophrenia, bipolar disorder, depression and anxiety disorders.

21 Sep 2010

Study examines effects of AEDs on nicotine metabolite levels in smokers

UMDNJ-Robert Wood Johnson Medical School researchers have determined that carbamazepine and oxycarbamazepine, medications commonly used to treat neurologic and psychiatric conditions, increase nicotine metabolism in smokers. As nicotine metabolism increases, cravings for nicotine return more quickly which could lead to more frequent cigarette consumption among individuals who also take these medications.

18 Sep 2010

Research suggests methodical approaches to control severe aggression among children with ADHD

Joseph C. Blader, Ph.D., Assistant Professor, Department of Psychiatry & Behavioral Science at Stony Brook University School of Medicine, and colleagues, found that almost half of children with attention-deficit/hyperactivity disorder whose aggressive behaviors had not been effectively controlled during routine outpatient care could achieve near absence of aggressive, explosive behavior when implementing "first-line" stimulant treatments for ADHD tailored to individual needs, along with behavioral therapy.

16 Sep 2010

Highlights of 23rd Congress of European College of Neuropsychopharmacology 2010

More than 7,000 psychiatrists, neurologists, psychologists and neuroscience researchers from all over the world met at the 23rd Congress of the European College of Neuropsychopharmacology (ECNP) from 28 August to 1 September 2010 in Amsterdam.

10 Sep 2010

NIH awards $6.5M for pharmacogenomics study of key mood-stabilizing drug for bipolar disorder

An international team, led by University of California, San Diego School of Medicine researchers, has been awarded a $6.5 million grant from the National Institutes of Health (NIH) to study the pharmacogenomics of a key mood-stabilizing drug used to treat bipolar disorder.

9 Sep 2010

NIH announces $161.3 million for expansion of Pharmacogenomics Research Network

The National Institutes of Health plans to spend $161.3 million over the next five years to expand the Pharmacogenomics Research Network (PGRN), a nationwide collaborative of scientists focused on understanding how genes affect a person's response to medicines.

8 Sep 2010

UC San Diego researchers receive grant to study pharmacogenomics for bipolar disorder

8 Sep 2010

Bipolar Disorder News and Research

Latest Bipolar Disorder News and Research

AstraZeneca launches new campaign on depression through Facebook and Twitter

Researchers use brain imaging to differentiate pediatric bipolar disorder, ADHD

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

NCQA recertifies Lilly's online Health Education Answers program

Valeant announces Alexza's receipt of FDA CRL for AZ-004 NDA

FDA issues CRL for AZ-004 NDA application

NBF's Brilliance in Bipolar Initiative receives Congressman Kennedy's endorsement

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Repligen Corporation completes patient enrollment in RG2417 Phase 2b clinical trial

Teens who experience manic phase of bipolar disorder more likely to engage in high risk sexual behaviors

USC, Las Encinas Hospital to study on schizophrenia, bipolar disorder in younger, older adults

Depression and anxiety disorders common in loved ones of breast cancer patients: Study

Antipsychotics slightly raise risk for blood clots

Haven Behavioral Hospital offers treatment programs for adults with psychiatric illnesses

Study examines effects of AEDs on nicotine metabolite levels in smokers

Research suggests methodical approaches to control severe aggression among children with ADHD

Highlights of 23rd Congress of European College of Neuropsychopharmacology 2010

NIH awards $6.5M for pharmacogenomics study of key mood-stabilizing drug for bipolar disorder

NIH announces $161.3 million for expansion of Pharmacogenomics Research Network

UC San Diego researchers receive grant to study pharmacogenomics for bipolar disorder

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Bipolar Disorder News and Research

Latest Bipolar Disorder News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in